Studying drugs in younger populations is challenging, and the scarcity of pediatric studies limits the ability of doctors and scientists to accurately predict drug dosing, safety and efficacy in children.
STUDYING DRUGS IN younger populations is challenging, and the scarcity of pediatric studies limits the ability of doctors and scientists to accurately predict drug dosing, safety and efficacy in children. Nearly 50% of products are labeled with pediatric information, indicating positive, negative or inconclusive results but not necessarily data supporting a specific indication for the drug, according to the U.S. Food & Drug Administration (FDA).
"Children with medical conditions require treatment of those conditions just as adults require treatment," says Lisa L. Mathis, MD, associate director, Office of New Drugs, FDA. "Clinicians are often forced to treat patients who require medical care without the benefit of data. While this may not be optimal, the lack of treatment may be worse."
To address this gap, last year the National Institutes of Health (NIH) developed an initiative, granting up to $95 million over the next seven years to conduct pediatric clinical trials in a safe environment and to weigh the benefits and risks of drug and device treatment in children. Danny Benjamin, MD, and his team at the Duke Clinical Research Institute, are the recipients of NIH's large grant, enabling trials to test drugs for life-threatening conditions and those for more common ailments among children.
The PREA allows the FDA to require studies when an application is submitted for a product with a new indication, active ingredient, formulation, dosing regimen or route of administration, Dr. Mathis says. Companies can receive waivers for the studies if the condition, targeted by the drug, does not occur or is rare in the pediatric population. The last two pieces of legislation sunset in 2012 but could be renewed.
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
The deliberate disconnection of Change Healthcare to ring fence a cyberattack entered its seventh day today. Prescribers are finding ways to get pharmacy claims processed, and UnitedHealth Group says disruption to the dispensing of prescriptions has been minimal. But independent pharmacies want more information and protection from financial consequences from pharmacy benefit managers.
Read More